Syndax
SNDX · United States
Share price · SNDX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SNDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-26.9%
- 3 Nov 2026+9.1%
- 13 Oct 2026-15.7%
- 16 Sep 2026-4.5%
Nothing announced by SNDX that day or the session before.
- 14 Jul 2026+5.4%
- 8 Jul 2026+5.7%
Nothing announced by SNDX that day or the session before.
- 26 Jun 2026+7.6%
Nothing announced by SNDX that day or the session before.
- 1 May 2026-10.8%
- 22 Apr 2026-5.4%
Nothing announced by SNDX that day or the session before.
- 2 Apr 2026+5.3%
Nothing announced by SNDX that day or the session before.
Share of unusual movement by asset
For each asset, the share of SNDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CSF-1RMonoclonal antibody | Graft-versus-Host Disease Chronic Graft-versus-Host Disease | |
| Approved | MeninSmall molecule | Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia Relapsed/Refractory Acute Myeloid Leukemia |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2028 (1)
May 2028 (1)
What to watch
2029 (2)
January 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $83M | $67M | $136M+ $291M short-term inv. | $49M-$27M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $73M | $68M | $336M+ $211M short-term inv. | $49M-$30M operating cash flow | report ↗ |
| 2026-Q1 | $65M | $59M | $131M+ $221M short-term inv. | $43M-$50M operating cash flow | report ↗ |
| 2025-Q3 | $46M | $56M | $117M+ $319M short-term inv. | $61M-$71M operating cash flow | report ↗ |
| 2025-Q2 | $38M | $62M | $109M+ $347M short-term inv. | $72M-$88M operating cash flow | report ↗ |
| 2025-Q1 | $20M | $62M | $154M+ $358M short-term inv. | $85M-$95M operating cash flow | report ↗ |
| 2024-Q3 | $13M | $71M | $133M+ $257M short-term inv. | $84M-$62M operating cash flow | report ↗ |
| 2024-Q2 | $3.5M | $49M | $105M+ $320M short-term inv. | $68M-$72M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $56M | $115M+ $320M short-term inv. | $72M-$84M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $39M | $95M+ $269M short-term inv. | $51M-$45M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $35M | $97M+ $302M short-term inv. | $45M-$35M operating cash flow | report ↗ |
| 2023-Q1 | — | $34M | $58M+ $375M short-term inv. | $41M-$39M operating cash flow | report ↗ |
| 2022-Q3 | — | $27M | $71M+ $266M short-term inv. | $35M-$29M operating cash flow | report ↗ |
| 2022-Q2 | — | $30M | $120M+ $247M short-term inv. | $38M-$40M operating cash flow | report ↗ |
| 2022-Q1 | — | $30M | $189M+ $209M short-term inv. | $37M-$42M operating cash flow | report ↗ |
| 2021-Q3 | $12M | $26M | $71M+ $158M short-term inv. | $21M-$25M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $172M | $259M | $135M+ $259M short-term inv. | $71M-$323M operating cash flow | report ↗ |
For FY2025, Syndax reported total revenue of $172.4M, up 627.8% YoY from $23.68M in the prior year. R&D expense was $258.8M, up 7.1% YoY. As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $394.1M. Net loss attributable to common stockholders was $285.4M, or $3.29 per share, compared to $318.8M in the prior year.
The company guided to full-year 2026 total R&D plus SG&A expense of approximately $400M, excluding an estimated $50M in non-cash stock compensation expense, and said its cash position, anticipated product and collaboration revenue, and interest income should support reaching profitability. Pipeline highlights included completed enrollment in the Phase 2 IPF trial of axatilimab with topline data expected in the fourth quarter of 2026, initiation of the REVEAL-ND Phase 3 trial of revumenib in newly diagnosed NPM1m AML, and ongoing combination trials across chronic GVHD and acute leukemia. Revuforj generated $124.8M in FY2025 net revenue, while Niktimvo generated $151.6M, with Syndax recording $42.4M in related collaboration revenue.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $24M | $242M | $154M+ $419M short-term inv. | $80M-$275M operating cash flow | report ↗ |
| 2023-FY | $0 | $163M | $295M+ $275M short-term inv. | $52M-$161M operating cash flow | report ↗ |
| 2022-FY | $0 | $119M | $74M+ $401M short-term inv. | $37M-$134M operating cash flow | report ↗ |
| 2021-FY | $140M | $88M | $222M+ $218M short-term inv. | —$29M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($2.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-09 | Ondrey Aaron · Chief Financial Officer | Award / grant (derivative) | 270,000 | $9.55 | $2.6M | Form 4 |
| 2026-10-29 | Podlesak Dennis · director | Option exercise | 8,000 | $11.81 | $94K | Form 4 |
| 2026-10-29 | Podlesak Dennis · director | Open-market sale | 8,000 | $14.21 | $114K | Form 4 |
| 2026-10-29 | Podlesak Dennis · director | Option exercise (derivative) | 8,000 | — | — | Form 4 |
| 2026-07-08 | Metzger Michael A · director, Chief Executive Officer | Option exercise | 32,375 | $6.38 | $207K | Form 4 |
| 2026-07-08 | Metzger Michael A · director, Chief Executive Officer | Open-market sale | 32,375 | $24.24 | $785K | Form 4 |
| 2026-07-08 | Metzger Michael A · director, Chief Executive Officer | Option exercise (derivative) | 32,375 | — | — | Form 4 |
| 2026-06-12 | Botwood Nicholas A.J. · Head of R&D, CMO | Option exercise | 31,235 | $13.82 | $432K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 244 reporting institutions held 100.5M shares ($2.3B, 112.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 8,254,426 | $192.8M |
| 2 | Kynam Capital Management, LP | 8,050,959 | $188.1M |
| 3 | GOLDMAN SACHS GROUP INC | 4,996,787 | $116.7M |
| 4 | STATE STREET CORP | 4,430,076 | $103.5M |
| 5 | BANK OF AMERICA CORP /DE/ | 4,249,836 | $99.3M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3,822,579 | $89.3M |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3,779,900 | $88.3M |
| 8 | Eversept Partners, LP | 2,885,622 | $67.4M |
| 9 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,500,000 | $58.4M |
| 10 | STEMPOINT CAPITAL LP | 2,431,486 | $56.8M |
| 11 | Hood River Capital Management LLC | 2,354,285 | $55.0M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 2,157,058 | $50.4M |
| 13 | FRANKLIN RESOURCES INC | 2,150,079 | $50.2M |
| 14 | Point72 Asset Management, L.P. | 1,985,547 | $46.4M |
| 15 | Elmind Capital, LP | 1,855,000 | $43.3M |